Ropinirole, a specific non-ergoline dopamine D2-receptor agonist, belongs to the drugs applied in treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) and acts as a D2, D3, and D4 dopamine receptor agonist with highest affinity for D3. Therapeutic ropinirole plasma levels in adults are defined between 0.4 and 6 ng/mL. This case report documents a fatal intoxication involving ropinirole. Information about lethal ropinirole concentrations is hitherto lacking in the literature and the assessed ropinirole levels of this case may present a step towards defining potentially lethal concentrations. A 37-year-old man without medical history was found dead in a converted van used as place of residence and an autopsy was performed. The pathological findings did not reveal an apparent cause of death but the toxicological analysis revealed the presence of ropinirole, paracetamol, and alcohol in the peripheral blood sample. Quantitative analysis revealed that ropinirole was present at a peripheral blood concentration of 64 ng/mL. The ropinirole concentrations determined in vitreous humor, urine and bile were respectively, 11 ng/mL, 2670 ng/mL and 826 ng/mL. Paracetamol was detected at a blood level of <2 μg/mL. Based on the autopsy findings and toxicological results, the cause of death was primarily attributed to intoxication with ropinirole in combination with alcohol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jflm.2012.04.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease.
J Neurol
January 2025
Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Background: Impaired impulse control is often seen in Parkinson's disease (PD) patients using dopamine agonists.
Methods: We performed a therapeutic drug monitoring study of 100 PD patients using ropinirole or pramipexole extended release. Three blood samples were collected on the same day.
Evaluating the Differential Effects of Dopamine Agonists and Clonazepam on Large Muscle Group Movements in Restless Legs Syndrome.
Sleep
January 2025
Clinical Neurophysiology Research Unit and Sleep Research Centre, Oasi Research Institute-IRCCS, Troina, Italy.
Study Objectives: This study aimed to investigate the effect of dopamine agonists (DA) and Clonazepam on Large Muscle Group Movements during sleep (LMM), a distinct motor phenomenon, in Restless Legs Syndrome (RLS).
Methods: A retrospective analysis was conducted on 51 drug-free adult patients with RLS, divided into three groups: 33 received a DA (pramipexole or ropinirole), 15 received clonazepam, and 18 received a placebo. Each patient underwent two consecutive nocturnal polysomnographic (PSG) recordings: one baseline and one following treatment administration.
Dopamine-D2-agonist targets mitochondrial dysfunction via diminishing Drp1 mediated fission and normalizing PGC1-α/SIRT3 pathways in a rodent model of Subarachnoid Haemorrhage.
Neuroscience
January 2025
Department of Medical Elementology & Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India. Electronic address:
The adverse impact of disturbmitochondrialbiogenesis onearly brain injury (EBI) following subarachnoid haemorrhage (SAH) has been broadly recognized and is closely associated with oxidative stress and neuronal apoptosis. Previous studies have indicated the therapeutic potential of Ropinirole, a dopamine D2 agonist, in Ischemic Stroke. However, there is a lack of evidence regarding the ability of Ropinirole to enhance mitochondrial biogenesis and quality control after subarachnoid haemorrhage.
View Article and Find Full Text PDFCase report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.
Front Immunol
October 2024
Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Article Synopsis
- - A patient experienced movement and neurocognitive toxicity after receiving ciltacabtagene autoleucel, which did not improve with standard immunosuppression treatments.
- - The patient's symptoms responded positively to a combination of dopaminergic therapies, including carbidopa/levodopa, ropinirole, and amantadine.
- - This case marks the first documented instance of effective symptomatic treatment for a well-known neurotoxic syndrome associated with this therapy.
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.
J Clin Sleep Med
January 2025
Department of Neurology, Vanderbilt University, Nashville, Tennessee.
Introduction: This guideline establishes clinical practice recommendations for treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) in adults and pediatric patients.
Methods: The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths based on a systematic review of the literature and an assessment of the evidence using the grading of recommendations assessment, development, and evaluation methodology. The task force provided a summary of the relevant literature and the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!